Abstract
Background: Heart failure (HF) is associated with type 2 diabetes mellitus (T2DM). Antihyperglycemic drugs have interaction with heart failure among diabetic patients. To date, the data on real world use of diabetic medication in Malaysian heart failure patients with T2DM has not been elucidated.Objective: This study aims to identify the prescribing pattern of antihyperglycemic regimens in HF patients with T2DM, and to investigate the association between glycemic control and other factors such as demographic and clinical characteristics with left ventricular ejection fraction (LVEF) in these patients.Methods: This retrospective observational study involved patients diagnosed to have HF and T2DM who were seen in the outpatient clinic in a government tertiary hospital in Malaysia. Patients receiving at least one oral antidiabetic agent and/or insulin for at least 3 months prior were included. The differences and association between study outcomes were examined and analyzed using Pearson's Chi-square test, One-Way ANOVA, Binary Logistic Regression and multiple Multinomial Logistic Regression models.Results: From July to December 2019, 194 patients were included in this study. The majority (52.1%) of the patients had HF with preserved ejection fraction (HFpEF), 20.6% had HF with mid-range EF (HFmrEF), and 27.3% had HF with reduced EF (HFrEF). Overall, metformin (59.8%) was the commonest antihyperglycemic agent prescribed, followed by insulins (54.0%), and sulphonylureas (44.9%). The most prescribed agents for HFpEF, HFmrEF, and HFrEF patients were metformin (65.3%), insulins (62.5%), and sulphonylureas (60.4%), respectively. The prescribing trend of sulphonylureas was found to be significantly associated with patients' LVEF status (p = 0.033). The odds for sulphonylurea prescription among the HFrEF patients were 2.42 times higher compared to the HFpEF patients [95% confidence interval [CI], 1.23–4.79]. There was no association found between glycemic control with patients' LVEF.Conclusion: Our findings reported metformin as the most commonly prescribed antihyperglycemic agent, sodium glucose linked transporter-2 (SGLT-2) inhibitor being under-prescribed, and detected poorly controlled diabetes in majority of patients with T2DM and HF. Understanding the prescribing pattern of antihyperglycemic agents supports the implementation of evidence-based treatment in HF patients with T2DM to improve patients' outcomes.
Highlights
Heart Failure (HF) is a progressive and chronic clinical syndrome characterized by typical symptoms of breathlessness, orthopnea, or ankle swelling, caused by a structural or functional cardiac abnormality, resulting in a decreased cardiac output and raised intracardiac pressures at rest or during stress [1]
Out of the 976 HF patients who had echocardiographic evidence of ejection fraction ≤ 70, 20.8% had a concomitant diagnosis of Type 2 diabetes mellitus (T2DM)
The prescribing patterns of antihyperglycemic agents varied amongst the three left ventricular ejection fraction (LVEF) subgroups
Summary
Heart Failure (HF) is a progressive and chronic clinical syndrome characterized by typical symptoms of breathlessness, orthopnea, or ankle swelling, caused by a structural or functional cardiac abnormality, resulting in a decreased cardiac output and raised intracardiac pressures at rest or during stress [1]. Heart failure is a global pandemic affecting at least 26 million people worldwide and is increasing in prevalence [2]. The prevalence of heart failure ranges between 3 and 20 per 1,000 population [3]. Type 2 diabetes mellitus (T2DM) is a prevalent noncommunicable disease characterized by hyperglycemia resulting from the combination of defects in insulin secretion, resistance to insulin action, and excessive glucagon secretion. Heart failure (HF) is associated with type 2 diabetes mellitus (T2DM). Antihyperglycemic drugs have interaction with heart failure among diabetic patients. The data on real world use of diabetic medication in Malaysian heart failure patients with T2DM has not been elucidated
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
